A growing body of research describes gal-9 as an independent biomarker for multiple autoimmune diseases, such assystemic lupus erythematosus (SLE) (Matsuoka et al., 2020), autoimmune hepatitis (AIH) (Matsuoka et al., 2019), systemic sclerosis (SSc) (Chihara et al., 2018), multiple sclerosis (MS) (Burman and Svenningsson, 2016), primary Sjogren’s syndrome (pSS) (van den Hoogen et al., 2020), and juvenile dermatomyositis (JDM) (Bellutti Enders et al., 2014; Wienke et al., 2019). This evidence concerns the gene LGALS9 and autoimmune hepatitis.